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The PIF-pocket of AGC protein kinases participates
in the physiologic mechanism of regulation by acting
as a docking site for substrates and as a switch
for the transduction of the conformational changes
needed for activation or inhibition. We describe the
effects of compounds that bind to the PIF-pocket
of PDK1. In vitro, PS210 is a potent activator of
PDK1, and the crystal structure of the PDK1-ATP-
PS210 complex shows that PS210 stimulates the
closure of the kinase domain. However, in cells, the
prodrug of PS210 (PS423) acts as a substrate-selec-
tive inhibitor of PDK1, inhibiting the phosphorylation
and activation of S6K, which requires docking to the
PIF-pocket, but not affecting PKB/Akt. This work
describes a tool to study the dynamics of PDK1
activity and a potential approach for drug discovery.
INTRODUCTION
Cells use protein phosphorylation to transduce information and
intracellular signals (Johnson and Lewis, 2001). Almost every
cellular signaling pathway is known to be regulated by phosphor-
ylation (Pawson andScott, 2005). Therefore, the action of protein
kinases and protein phosphatases is essential for multiple phys-
iologic responses. The uncontrolled action of protein kinases
can result in diseases, such as cancer, diabetes, and neurologic
disorders, making protein kinases a highly sought-after drug
target class in the pharmaceutical industry (Cohen, 2002).
The activation of protein kinases often involves phosphoryla-
tion, regulation by N- or C-terminal domains or regulation by
interacting partners. The cAMP-dependent protein kinase PKA
is a prototype for the structural studies on the catalytic domain
of protein kinases. A number of crystal structures show the cata-
lytic subunit in ‘‘open,’’ ‘‘closed,’’ and ‘‘intermediate’’ conforma-
tions that reflect the relative motions between the small and the
large lobes of the protein. The transition to the close-active1152 Chemistry & Biology 19, 1152–1163, September 21, 2012 ª201conformation of PKA is induced by ATP and peptide binding
to the substrate binding sites (Johnson et al., 2001; Knighton
et al., 1991a, 1991b). In PKA, as well as in other kinases from
the AGC group, the Phe residues within the C-terminal sequence
(Phe-Xaa-Xaa-Phe-COOH) bind to the small lobe of the kinase
domain in a hydrophobic pocket termed the ‘‘PIF-pocket.’’ These
Phe residues are necessary for activity in PKA (Batkin et al.,
2000; Etchebehere et al., 1997). However, neither the opening-
closing of the domains nor the Phe-Xaa-Xaa-Phe-COOH motif
appears to play a central role in the stimulus-induced regulation
of PKA activity. In contrast, other AGC kinases possess an
extended hydrophobic motif (HM) comprising the equivalent
Phe residues followed by a phosphorylation site (Phe-Xaa-Xaa-
Phe-Ser/Thr-Tyr, where the phosphorylated amino acid is under-
lined), which participates in the stimulus-induced regulation of
the activity of AGC kinases by interacting with the PIF-pocket
in a phosphorylation-dependent manner (Biondi, 2004; Fro¨din
et al., 2002; Pearce et al., 2010; Pearl and Barford, 2002; Yang
et al., 2002). In atypical PKCs, the PIF-pocket mediates the inhi-
bition by theN-terminal domain (Lopez-Garcia et al., 2011). Thus,
even if the mechanism of regulation of the different AGC kinases
is different, they seem to converge on the PIF-pocket.
In target cells, insulin induces the activation of the phosphoi-
nositide 3-kinase (PI3-kinase), which catalyzes the synthesis of
the second messenger phosphatidylinositol (3,4,5)-triphosphate
(PIP3) at the plasma membrane (Figure 1). In the presence of
PIP3, the phosphoinositide-dependent protein kinase 1 (PDK1)
and protein kinase B (PKB, also termed Akt) rapidly colocalize
at the plasma membrane where PDK1 phosphorylates the acti-
vation loop of PKB/Akt, activating this enzyme. Active PKB/Akt
then transduces a number of insulin effects, such as those
leading to glucose uptake and the synthesis of glycogen in
muscles (Vanhaesebroeck and Alessi, 2000).
With a slower time course following insulin stimulation, PDK1
also phosphorylates the activation loop of the serum- and gluco-
corticoid-stimulated kinase (SGK), p70 ribosomal S6 kinase
(S6K), protein kinase C-related kinase (PRK), and p90 ribo-
somal S6 kinase (RSK) isoforms (Vanhaesebroeck and Alessi,
2000). Other substrates of PDK1, like classical protein kinase C
(PKCs), appear to be phosphorylated by PDK1 constitutively2 Elsevier Ltd All rights reserved
Figure 1. Role of PDK1 in the Insulin
Signaling Pathway
The binding of insulin or growth factors to the
insulin receptor results in the autophosphorylation
of a number of tyrosine residues that are present in
the receptor and recognized by members of the
insulin receptor substrate (IRS) family. The insulin
receptor also phosphorylates key tyrosine resi-
dues on IRS proteins, some of which are recog-
nized by the SH2 domain of the p85 regulatory
subunit of phosphoinositide 3-kinase (PI3K). The
catalytic subunit of PI3K, p110, then phos-
phorylates phosphatidylinositol 4,5-bisphosphate
(PIP2), leading to the formation of phosphatidyli-
nositol (3,4,5)-triphosphate (PIP3) at the plasma
membrane. This phosphorylation allows for the
recruitment of PDK1 and PKB to the plasma
membrane via their PH domains. PDK1 then acti-
vates PKB by phosphorylating T308 in its activa-
tion loop. PKB plays a key role in mediating the
glucose uptake and glycogen synthesis after
insulin stimulation in skeletal muscles.
With a slower time course following insulin stimu-
lation, PDK1 phosphorylates and activates S6K.
The interaction and subsequent activation is
triggered by the docking of the phosphorylated
hydrophobic motif (HM) of S6K in the PIF-binding
pocket and an associated phosphate-binding site of PDK1. Active S6K can phosphorylate several substrates, including the ribosomal S6 protein. S6K can also
desensitize the insulin receptor by phosphorylating several serines in IRS-1, creating a negative feedback loop that inhibits PI3K downstream signaling.
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Mechanism for Substrate-Selective PDK1 Inhibition(Newton, 2003). The difference in the timing of substrate phos-
phorylation can be explained by the different molecular mecha-
nisms of recognition and interaction between PDK1 and its
substrates (Biondi et al., 2001; Leslie et al., 2001). In contrast
to PKB/Akt, all other AGC kinase substrates of PDK1 described
so far require docking of their HM to the PIF-binding pocket of
PDK1 to become phosphorylated (Biondi, 2004; Biondi et al.,
2001). Biochemical studies showed that PIFtide and phosphory-
lated HM polypeptides derived from substrates of PDK1 bound
to the PIF-binding pocket of PDK1 and activated PDK1 in vitro
(Biondi et al., 2000; Engel et al., 2006; Fro¨din et al., 2000). Fur-
thermore, crystallography studies identified a sulfate-binding
site contiguous to the hydrophobic PIF-binding pocket (Biondi
et al., 2002), and biochemical evidence confirmed that the resi-
dues that form part of this site participated in the binding to
the phosphorylated HM (Biondi et al., 2002; Fro¨din et al.,
2002). The phosphorylation of the HMof SGK, RSK and S6K trig-
gers the interaction of the substrate kinase with the PIF-binding
pocket and the associated phosphate-binding site on PDK1
(Biondi, 2004; Pearce et al., 2010), although the sequence of
events is contested in the case of S6K (Keshwani et al., 2011).
This model suggests that the requirement for previous phos-
phorylations could be at the heart of the different timing of
phosphorylation of PDK1 substrates. As a consequence of the
docking of the HM of substrates to the PIF-binding pocket of
PDK1, a conformational change in PDK1 is triggered, stimulating
its activity and subsequent phosphorylation of the protein kinase
substrate at the activation loop. Elegant knock-in experiments
where the endogenous PDK1 was replaced with a PDK1 pro-
tein mutated at the center of the PIF-binding pocket (PDK1
Leu155Glu) or at the phosphate-binding site, confirmed that
the PIF-binding pocket of PDK1 and its associated phosphate-Chemistry & Biology 19, 1152–116binding site are necessary for the phosphorylation of S6K but
not PKB/Akt in vivo (Collins et al., 2003, 2005). Thus, in vitro
and in vivo studies using mutants of the PIF-binding pocket sug-
gested that the integrity of the pocket is required for the docking
of several substrates of PDK1.
Following insulin stimulation, activated S6K phosphorylates its
substrates, including the ribosomal S6 protein and elongation
factor 2-kinase that support insulin-stimulated protein synthesis.
In adipocytes and muscle cells, S6K also phosphorylates IRS1,
which is an adaptor protein that links the insulin receptor to the
p85 regulatory subunit of PI3-kinase. Phosphorylation of IRS1
by S6K acts as a negative feedback loop, inhibiting PI3-kinase
downstream signaling (Tremblay et al., 2007; Um et al., 2004).
Constitutive activation of this negative feedback loop may be
at the center of insulin resistance and diabetes. Indeed, in-
creased S6K1 activity is associated with impaired glucose
tolerance in humans (Barbour et al., 2011). Collectively, the
knowledge about the S6K-IRS1 negative feedback loop high-
lighted S6K as a possible target to sensitize organisms to insulin
action for the treatment of type II diabetes (Boura-Halfon and
Zick, 2009; Harrington et al., 2004). In agreement with this possi-
bility, S6K knock-out mice are protected against obesity induced
by age or diet and have an increased sensitivity to insulin (Um
et al., 2004, 2006).
In previous work, we developed low molecular weight com-
pounds that bind in the PIF-binding pocket of PDK1 and activate
this kinase in vitro (Engel et al., 2006; Hindie et al., 2009; Stroba
et al., 2009). Additional structural and biochemical experiments
indicated that the binding of activator compounds to the
PIF-binding pocket transduces allosteric effects to the ATP-
binding site (Hindie et al., 2009), although the full molecular
details of the activation process remain unknown. Recently,3, September 21, 2012 ª2012 Elsevier Ltd All rights reserved 1153
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Figure 2. Dicarboxylate Compounds, but Not
Their Di-Ester Prodrugs, Are In Vitro Activa-
tors of PDK1
The activity of purified full-length PDK1 and its
mutants was measured in vitro using the poly-
peptide T308tide as a substrate in the presence of
PIFtide or small compounds.
(A) The structures of the low molecular weight
compounds described in this study.
(B) The activation of PDK1 by the dicarboxylates
PS210 (AC50 2 mM) and PS182 (AC50 2 mM), relative
to that of PS48.
(C) Results of activity assays with PDK1 wt and
mutants identify the PIF-binding pocket as the
target site for PS210. This compound can activate
PDK1 wt but not proteins with mutations in the
PIF-binding pocket. The di-ester prodrug, PS423,
does not activate PDK1 wt or the mutant proteins.
See also Figure S1.
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Mechanism for Substrate-Selective PDK1 Inhibitionsmall compounds that activate PDK1 have also been reported
by others (Stockman et al., 2009; Wei et al., 2010). However,
most of the compounds described to date contain groups that
do not allow for the passive diffusion of the compounds into
cells. In the present work, we describe both themolecular details
by which allosteric PIF-binding pocket compounds induce a
close-active conformation of PDK1 in vitro and the effects of
prodrug cell-permeable derivative compounds that are cleaved
intracellularly to the corresponding active compounds. Treat-
ment of cells with the prodrug PS423 inhibited S6K signaling
without affecting PKB/Akt downstream effects in HEK293 or in
C2C12 myoblast cells. Notably, PS423 allowed us to elucidate
the existence of at least three different PDK1-dependent path-
ways participating in the insulin-stimulated glucose uptake in
C2C12 myoblasts and myotubes. These results open the field
for the development of future substrate-selective protein kinase
inhibitor drugs that may have use in the treatment of human
diseases, including cancer and diabetes.
RESULTS
The Dicarboxylates PS182 and PS210, but Not Their Di-
Ester Derivatives, Are Potent Activators of PDK1 In Vitro
We previously developed low molecular weight compound acti-
vators of PDK1 consisting of two ring systems joined by a linker
and an additional side chain ending in a carboxyl group (e.g.,
compound 1 and PS48, Figure 2A) (Hindie et al., 2009; Stroba
et al., 2009). This carboxyl moiety interacts with three residues
that form part of the HM-phosphate-binding site on PDK1, which
is participating in the physiologic activation of PDK1. We specu-
lated that a compound with two carboxyl groups might more
efficiently mimic a phosphate and be a more potent activator
of PDK1. Therefore, we synthesized a series of low molecular1154 Chemistry & Biology 19, 1152–1163, September 21, 2012 ª2012 Elsevier Ltd All rightsweight dicarboxylate compounds (Fig-
ure 2A). We observed that PS182 (con-
taining the two ring systems as in
compound 1 and PS48) and PS210 (with
a trifluoromethyl substitution of the chlo-
rine) were very potent activators ofPDK1 (Figure 2B). Notably, PS210 stimulated 650% of basal
PDK1 activity, which is 2-fold higher than the maximal activation
obtained for our previously described compound, PS48.
The study of compound 1 and the family of PS48 compounds
in cells has so far been severely hampered by these compounds’
lack of cell permeability that is due to the negative charge asso-
ciated with the carboxyl group. Therefore, to investigate the
pharmacologic effects of blocking the PIF-binding pocket of
PDK1 with more potent compounds, we synthesized di-ester
(bis-acetoxymethyl ester) derivatives of PS210 (PS423) and
PS182 (PS220). We reasoned that these di-ester derivatives
would act as cell-permeable prodrugs and could be cleaved
by cellular esterases to form the corresponding dicarboxylate
variants. PS423 did not affect the activity of PDK1 in vitro, indi-
cating that the carboxyl groups of the compounds are required
for activation of PDK1 (Figure 2C). PS210 loses the ability to acti-
vate PDK1 upon mutation of Leu155 to Glu, Val127 to Leu or
Arg131 to Met, suggesting that the interaction between this
compound and PDK1 requires the PIF-binding pocket and that
an interaction with the positive charge from Arg131 is important
for the activation of PDK1. Mutation of other residues within the
PIF-binding pocket resulted in intermediate effects, suggesting
that these residues are not essential for the binding and activa-
tion by the dicarboxylate compounds.
We originally described the PIF-binding pocket as the site on
PDK1 that interacted with PIFtide (REPRILSEEEQEMFRDFDYIA
DWC), a polypeptide derived from the HM of PRK2. PIFtide
interacts with PDK1 with high affinity (50 nM), and surface plas-
mon resonance studies revealed that 50% of the dissociation
occurred within 40–60 s (Biondi et al., 2000), indicating a low
OFF-rate. Here, we demonstrate that the interaction between
His-PDK1 (50–360) and biotin-PIFtide can also be detected in
an AlphaScreen assay (Figures S1A and S1B available online).reserved
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Figure 3. Increased Thermal Stability of PDK1 in the Presence of
PS182 and PS210
The thermal stability of PDK1 in the presence of compounds was assessed by
differential scanning fluorimetry (DSF) (see also Figure S2). For each condition,
the midpoint temperature of transition, or Tm, of PDK1 was calculated. This
value changes in the presence of an interacting compound (DTm = Tm – T0). The
data points reflect the averages of a duplicate experiment ± standard devia-
tions. PS182 and PS210 stabilize PDK1 in a concentration-dependent fashion,
whereas the di-ester prodrugs PS423 and PS220 show variations only around
the standard deviation for T0, which is 0.3
C (indicated by n.s., not significant).
PS48, on the other hand, destabilizes PDK1, which can be concluded because
the shifts at the higher concentrations were greater than two times the stan-
dard deviation for T0 (indicated by the asterisk).
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Mechanism for Substrate-Selective PDK1 InhibitionWe show that PS182 and PS210, but not PS48, were able to fully
displace the high-affinity interaction between PDK1 and PIFtide
(Figure S1C). Together, mutagenesis analysis and the displace-
ment of the interaction are consistent with the idea that PS182
and PS210 bind with high affinity to the PIF-binding pocket
of PDK1.
PS182 and PS210, but Not PS48, Increased the Thermal
Stability of PDK1
ATP-competitive compounds have been shown to stabilize
different protein kinases up to 20C in a temperature stability
assay (Fedorov et al., 2007; Niesen et al., 2007). Similarly, the
melting temperature of PDK1 shifts by 20C in the presence
of UCN-01, a derivative of staurosporine (Figure 3). In com-
parison to UCN-01, we observed a rather modest stabili-
zation of PDK1 of up to 4C for PS210 and PS182, which is in
agreement with the stabilization induced by PIFtide and with
previous findings for other allosteric ligands of PDK1 (Bobkova
et al., 2010). The di-ester derivatives PS423 and PS220 did
not affect the melting temperature of PDK1, which is in agree-
ment with their lack of effect on PDK1 activity. Interestingly,
PS48 did not stabilize full length PDK1 in this assay, but it
prompted a small concentration-dependent loss of stability
to the temperature gradient. Similarly, PS210 increased the
stability of the isolated catalytic domain of PDK1 (residues
50–359) by 4C, whereas PS48 had virtually no effect (Fig-
ure S2). The data indicate that the dicarboxylic compounds
PS182 and PS210 stabilize PDK1 but that this stabilization
is not required for activation because PS48 has almost noChemistry & Biology 19, 1152–116effect on the stability or destabilizes PDK1 to the temperature
treatment.
The Crystal Structures of PS182 and PS210 Confirm
Their Binding to the PIF-Binding Pocket of PDK1 and
Provide Molecular Details on the Mechanism of
Allosteric Activation
We previously crystallized and solved the structure of a trun-
cated version of PDK1 that consists of the catalytic domain
(residues 50–359) comprising two additional mutations (Y288G
and Q292A) in complex with ATP and in complex with both
ATP and PS48 (both at 1.9 A˚ resolution) (Hindie et al., 2009).
We now present crystal structures of PDK1 in complex with
ATP/PS182 (1.43 A˚) and ATP/PS210 (1.68 A˚) (Figure 4; Table S1).
In agreement with the biochemical data and similarly to PS48,
both compounds bind to the PIF-binding pocket in the small
lobe of PDK1, with both rings occupying the two subpockets
and one carboxyl group interacting with and stabilizing Lys76,
Arg131, and Thr148 (Figures 4A–4C). The second carboxyl
group from PS182 and PS210 forms an additional salt bridge
with Arg131. Because this additional interaction is not present
in PS48, this interaction is expected to be responsible for
the higher affinity of PS182 and PS210 as compared with that
of PS48.
Both dicarboxylate compounds induce a significant 1.0 A˚
downward motion of helix a-B toward the active site (Figures
4D–4F). However, only compound PS210 closes the structure
of the catalytic domain of PDK1. PS210 causes a further shift
of helix a-B perpendicular to the first movement and along the
axis of the helix by 1.1 A˚. This combined conformational shift is
accompanied by an upward movement of helix a-C by 1 A˚
and, more importantly, by a rotational motion of the whole anti-
parallel b sheet that forms the core of the small lobe. Most
notably, the conformational change that originates from com-
pound PS210 allosterically binding to the PIF-binding pocket is
relayed to the active site where the Gly-rich loop, which consti-
tutes the upper part of the ATP-binding pocket, is displaced by
approximately 1.4 A˚ (Figure 4G). This conformational change
induces a very important relocation of the ATP phosphate
groups (Figures 4H and 4I). In particular, the previously uncoor-
dinated b-phosphate is rotated by approximately 120 and now
interacts with residues Asp223, Lys111, and Ser94 of the Gly-
rich loop. Thus, the PS210-bound structure of PDK1 is very
similar to the PKA structure (PDB code 1ATP) in complex with
ATP and the peptide inhibitor PKI, which is believed to represent
the fully close-active conformation of PKA. Interestingly, in the
ATP-binding pocket we now observe strong electron density
for small molecules, two of which are not compatible with water
molecules as a result of high coordination numbers and short
binding distances (up to 2.0 A˚), that may correspond to divalent
cations. Because the X-ray absorption edge for Mg2+ is not
within the range of synchrotron beamlines, we soaked a crystal
of PDK1 with PS210 and substituted MgCl2 by MnCl2. After
transfer of the phases from a high resolution data set, the result-
ing anomalous densitymap showed a very strong peak for one of
the suspected metal ions and confirms this to be Mn2+ or Mg2+.
This ion tethers the b- and g-phosphates of ATP to the Asp223 of
the DFG motif. For the other metal ion, no anomalous density
was observed, thus it is expected to be ametal with a lower order3, September 21, 2012 ª2012 Elsevier Ltd All rights reserved 1155
Figure 4. Crystal Structures of PDK1 Bound to PS182 and PS210
(A–C) Crystal structures of PDK1 in complex with allosteric compounds PS48 (PDB code 3HRF) (A), PS182 (B), and PS210 (C). PDK1 is shown in cartoon
representation. Only residues contributing to the PIF-binding pocket are shown in stick representation and hydrogen bond interactions are indicated by gray
dashed lines. j2Fo-Fcj electron density of the compounds is indicated in blue and contoured at 1s.
(D) Comparison of unbound PDK1 (yellow; PDB code 3HRC) with the structures containing PS182 (green) and PS210 (orange). For simplicity, ATP is only shown
for the PS210 co-crystal structure.
(E and F) Both dicarboxylate compounds caused a downward motion of helix aB. But only PS210 caused an additional upward shift of helix aC and a rotational
movement of large parts of the small lobe.
(G–I) This additional movement converted PDK1 to a close-active conformation by pushing down the glycine-rich loop of the ATP-binding pocket (G). In
comparison to the unbound structure (PDB code 3HRC) (H), the ATP of the PS210 structure (I) changed its conformation. In particular, the b-phosphate rotated by
approximately 120. b- and g-phosphate are now bound by a Mg2+ ion to Asp223 of the DFG motif. Mg2+ was replaced by Mn2+. Anomalous electron density of
the Mn2+ ion is shown in purple and contoured at 3s.
See also Table S1.
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Mechanism for Substrate-Selective PDK1 Inhibitionnumber, most likely a Na+ ion, which is present in high concen-
trations in the crystallization and soaking solutions.
PS210 Specifically Targets PDK1 In Vitro
To assess the selectivity of PS210 against kinases other than
PDK1, a kinase profiling study was carried out. PS210 did not
alter the activity of any of the 121 kinases tested in this panel,
including PDK1 downstream signaling components such as
S6K, PKB/Akt or GSK3 (Table S2).
Remarkably, PDK1 activity remained unchanged in the pres-
ence of PS210 in the outsourced profiling study, which employs1156 Chemistry & Biology 19, 1152–1163, September 21, 2012 ª201PDKtide as a substrate (instead of T308tide used by us in our
characterizations). PDKtide was designed as an improved sub-
strate by joining PIFtide with T308tide into one polypeptide.
The docking of the PIFtide sequence to the PIF-binding pocket
of PDK1 resulted in PDKtide being a vastly improved substrate
in comparison to T308tide (Biondi et al., 2000). However, PIFtide
alone already has a high affinity and low OFF-rate for PDK1.
Therefore, it may be difficult to displace the interaction of the
39-amino acid polypeptide PDKtide from PDK1 with small com-
pounds. Indeed, in parallel experiments, we could verify that
PS210 potently activates PDK1 using T308tide as a substrate,2 Elsevier Ltd All rights reserved
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Figure 5. PS423 Inhibits S6K but Not PKB/Akt Downstream Signaling in HEK293 Cells
The immunoblots showing the effects of PS210 and its di-ester prodrug PS423 on the PDK1 signaling pathway in HEK293 cells (left panels) and the quantification
of the signals by normalizing to the b-actin signal (right panels, averages of the duplicate samples ± standard deviations are shown).
(A) HEK293 cells were preincubated with 100 mMPS210 and 50 mM or 100 mMPS423 for 2 hr and stimulated with IGF1 20 min prior to lysis, and western blotting
using antibodies against phosphorylated S6 and against the activation loop phosphorylation of PKB/Akt.
(B) GST-S6K[T412E] (containing a negatively charged residue in place of the HM phosphorylation site) was overexpressed in HEK293 cells to investigate the
phosphorylation of its activation loop and of the substrate S6 after incubation with 50 mM PS423 and stimulation by IGF1.
(C) 50 mM PS423 inhibits the phosphorylation of S6 also without prior stimulation with IGF1, reflecting the effect of the compound on the basal activity.
See also Figure S3 and Table S2.
Chemistry & Biology
Mechanism for Substrate-Selective PDK1 Inhibitionbut does not affect the activity of PDK1 using PDKtide as
a substrate (Figure S3). Therefore, we conclude that PS210 is
a highly selective compound activator of PDK1 that does not
affect the activity of the 120 other protein kinases tested.
The PS210 Prodrug Compound PS423 Inhibits S6K but
Not PKB/Akt DownstreamSignaling inHEK293Cells and
C2C12 Myoblast Cells
The above data indicated that PS182 and PS210 were potent
activators that target the PIF-binding pocket of PDK1. To test
the effect of blocking the PIF-binding pocket pharmacologically
in cells, we employed PS220 and PS423, the di-ester derivatives
of PS182 and PS210, respectively. PS220 was relatively toxic,
resulting in the detachment of the HEK293 cells in culture.
PS423 was cleaved intracellularly to render PS210 (A.S.,
L.A.L-G., K.B., Wolfgang Fro¨hner, Frauke Maurer, Stefan
Boettcher, J.O.S., Hua Zhang, R.M.B., and M.E., unpublished
data). Therefore, we used PS423 for subsequent experiments.
In the first set of experiments, HEK293 cells were serum-starvedChemistry & Biology 19, 1152–116overnight, incubated for 2 hr with PS423 (50 mM) or PS210 and
stimulated with IGF1 for 20 min. The prodrug PS423 potently in-
hibited the phosphorylation of S6, a substrate of S6K (Figure 5A).
At the same concentrations that resulted in 83% and 95% inhibi-
tion of S6 phosphorylation, we observed only aminor decrease in
PKB/Akt activation loop phosphorylation. This result is in agree-
ment with the previous findings using mutant PDK1 proteins that
indicated that docking to the PIF-binding pocket is not necessary
for the phosphorylation and activation of PKB/Akt by PDK1.
To correlate the decrease in the phosphorylation of S6 with
a diminished phosphorylation of the S6K activation loop [T229]
by PDK1, GST-S6K[T412E] (containing a negatively charged
residue in place of the HM phosphorylation site) was overex-
pressed in HEK293 cells. After overnight serum starvation these
cells were incubatedwith 50 mMPS423 for 4 hr, followed by stim-
ulation with IGF1 20 min prior to cell lysis. PS423 produced a
strong decrease in the activation loop phosphorylation of S6K,
in agreement with the reduced S6 phosphorylation (Figure 5B).
A similar reduction in S6 phosphorylation was obtained for cells3, September 21, 2012 ª2012 Elsevier Ltd All rights reserved 1157
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Figure 6. PS423 Inhibits S6K but Not PKB/Akt Downstream Signaling in Muscle Cells
Immunoblots showing the effects of the di-ester prodrug PS423 on the PDK1 signaling pathway in C2C12 myoblasts (left panels) and the quantification of the
signals by normalizing to the b-actin signal (right panels, averages ± standard deviations are shown).
(A) C2C12 cells were preincubated with 25 mMPS423 for 2 hr, and then activation of the signaling pathway was achieved by the addition of insulin (incubation for
15 or 60 min). The phosphorylation statuses of S6, the activation loop of PKB/Akt, the hydrophobic motif of PKB/Akt and GSK3 were verified using the indicated
antibodies. The quantification of the phospho-PKB(S473) and phospho-GSK3 signals is shown in Figure S4.
(B) To verify the effect of PS423 on the basal kinase activity, C2C12 cells were incubated for 4 hr with 25 mM PS423, followed by immunoblot analysis using the
antibody against the phosphorylated S6.
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Mechanism for Substrate-Selective PDK1 Inhibitionthat were not stimulated with IGF1, reflecting the basal turnover
of S6 phosphorylation (Figure 5C). Altogether, these results
suggest that PS423, the prodrug compound of PS210, inhibits
S6K activity without affecting the PKB/Akt signaling pathway in
HEK293 cells.
We then addressed the pharmacologic effects of PS423
in a physiologically more relevant system. To this end, we
employed the C2C12 myoblast cell line and preincubated the
cells with 25 mM PS423 for 2 hr. Activation of the PDK1
signaling pathway was achieved by incubating the cells for 15
or 60 min with insulin (Figure 6A). The phosphorylation of S6
was inhibited by PS423, whereas no significant reduction in
PKB/Akt activation loop phosphorylation was detected. Further-
more, we observed no decrease in the phosphorylation of either
the PKB/Akt HM S473 residue or, more downstream, GSK3, a
substrate of PKB/Akt (Figures 6A and S4). Similar to the findings
in HEK293 cells, a reduction (70%) was observed in the basal S6
phosphorylation after a longer preincubation (4 h) of the
myoblast cells with the compound (Figure 6B), indicating that
the S6 protein is actively phosphorylated and dephosphorylated
in serum-starved cells. Thus, as previously observed in HEK293
cells, PS423 inhibited S6K activity but not PKB/Akt downstream
signaling in C2C12 myoblast cells, confirming that PS423 can
selectively inhibit the phosphorylation of PDK1 substrates. The
results confirm the substrate-selective requirement of the
PIF-binding pocket of PDK1 by using pharmacologic tools.1158 Chemistry & Biology 19, 1152–1163, September 21, 2012 ª201PS423 Differentially Inhibits Glucose Uptake in C2C12
Myoblasts but Not in C2C12 Myotubes
We next tested the effect of 25 mM PS423 on glucose uptake
in C2C12 myotubes cells (Figure 7A). Insulin stimulated the glu-
cose uptake by 45%. In agreement with the fact that PDK1medi-
ates PKB/Akt phosphorylation and activation, the non-selective
PDK1 inhibitor UCN-01 completely blocked the insulin-stimu-
lated glucose uptake. In addition, UCN-01 also decreased the
basal levels of glucose uptake. In parallel, the insulin-mediated
increase of glucose uptake was blocked to basal levels in the
presence of rapamycin, a TORC1 inhibitor that blocks S6K acti-
vation, or in the presence of PS423. Thus, the results are consis-
tent with the idea that, in C2C12 myotubes, both substrates of
PDK1, S6K, and PKB/Akt, may be involved in the basal and
insulin-stimulated glucose uptake.
C2C12 myoblast cells (C2C12 cells that were not differenti-
ated to myotubes) also responded to insulin by increasing their
glucose uptake (Figure 7B). However, in contrast to the results
obtained using C2C12 myotubes, we unexpectedly found that
PS423 completely inhibited the basal and insulin-stimulated
glucose uptake in C2C12 myoblasts cells. As a control, the cell
viability (MTT assay) eliminated any potential toxic effect by
PS423 (Figure S5). A western blot analysis demonstrated that
under these experimental conditions the phosphorylation of S6
was inhibited to 50% by PS423, whereas PKB/Akt phosphoryla-
tion was not affected by the treatment. Therefore, the results2 Elsevier Ltd All rights reserved
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Figure 7. PS423 Inhibits Glucose Uptake in C2C12 Myoblasts but
Not in C2C12 Differentiated Muscle Cells
Glucose uptake wasmeasured following insulin stimulation in C2C12 cells that
were differentiated to myotubes (A) or in undifferentiated myoblasts (B) and
incubated with 25 mM UCN-01 (left panels) or 25 mM PS423 and 25 nM
rapamycin (right panels). The basal activity before insulin stimulationwas set to
100%. The data points represent the averages ± the standard deviations of
duplicate (left panels) or triplicate (right panels) experiments. Related western
blot analysis and MTT results are shown in Figure S5.
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stimulated glucose uptake in C2C12 myoblasts. Interestingly,
rapamycin completely inhibited S6 phosphorylation, but only
partially blocked glucose uptake. Therefore, the results sug-
gested that S6K and an additional protein kinase dependent
on the PIF-binding pocket of PDK1 were responsible for
the basal and insulin-stimulated glucose uptake in C2C12
myoblasts.
In conclusion, the use of PS423 revealed that different PDK1-
dependent signaling kinases are involved in glucose uptake in
C2C12 myoblasts and myotubes, one independent of the PIF-
binding pocket of PDK1 (PKB/Akt), and at least two different
kinases that are dependent for their activation on the docking
to the PIF-binding pocket of PDK1.
DISCUSSION
Despite its potential importance, the rational design of small
compounds to mimic the conformational changes physiologi-
cally induced by phosphorylation is hampered by the lack ofChemistry & Biology 19, 1152–116structural data and by the challenge of rationalizing the develop-
ment of compounds into pockets that dynamically change shape
and transduce conformational changes in ways that are only
vaguely understood. We described dicarboxylate allosteric acti-
vators of PDK1 that extensively mimic the interactions between
the phosphate-binding site of PDK1 and its phophorylated HM
and evaluated the properties of the new phosphate-mimic com-
pounds in vitro and in cultured cells. Our results show that the
major cellular effect of the binding of the compounds to the
PIF-binding pocket of PDK1 is the blockage of the pocket, which
is independent of whether the compound is an activator in vitro.
The resulting compounds are substrate-selective inhibitors of
PDK1 activity in cells and allowed us to distinguish different
PDK1-dependent signaling pathways that differed in their re-
quirement for the PIF-binding pocket of PDK1. Together, the
development of small compounds that target the regulatory allo-
steric PIF-pocket of AGC kinases suggests that the site provides
a source for the development of allosteric activators, allosteric
inhibitors, and substrate-selective inhibitors with potential use
in research and for the selective regulation of signaling pathways
involved in human diseases. Future drug development programs
could benefit from an analogous approach to develop com-
pounds that mimic or antagonize phosphorylation-dependent
conformational changes.
Phosphorylation can lead to the activation of enzymes by
promoting stability or disorder within the molecule. Our data
suggest that the overall neutral or loss of thermal stability in
the presence of PS48 is due to a proportionally similar loss of
stability of residues from the a-B and a-C helices relative to the
stabilization of the phosphate binding site residues. Altogether,
neither the overall stabilization of the protein nor the stability of
the a-B and a-C helices appeared to be required for compounds
to activate PDK1. The finding that activators do not necessarily
increase the overall thermal stability of the target may impact
on drug discovery approaches to similar allosteric sites, most
notably, by careful re-evaluation of thermal stability filtering
steps along the process of prioritization of compounds. How-
ever, even when they induced a stabilization of PDK1 to the
temperature gradient (PS182 and PS210) or its destabilization
(PS48), all three activators stabilized the residues Thr148,
Arg131, and Lys76, located opposite to the helix a-B at the other
extreme of the helix a-C. Thus, the residues forming part of the
phosphate-binding site appear to be a fixed point that allows
for the relative movement of the helices in the process of PDK1
activation.
Previous hydrogen-deuterium exchange experiments indi-
cated that the helix a-C, within the PIF-binding pocket, is very
disordered in solution (Hindie et al., 2009). The initial binding of
the small compound activator could take place essentially by
conformational sensing of the appropriate conformation of the
PIF-binding pocket of PDK1. Alternatively, initial binding could
be triggered by interaction of the carboxylates with positively
charged residues and thereafter the compound could accom-
modate into the pocket by induced-fit mechanisms. Indepen-
dently of the mechanism of initial binding, it is tempting to
speculate that the fixing of residues at the phosphate-binding
site at one extreme of the helix a-C, together with additional
specific interactions of the compound with the helix a-B, would
limit the possible movements of the helices a-B and a-C and3, September 21, 2012 ª2012 Elsevier Ltd All rights reserved 1159
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at the ATP-binding site by induced-fit mechanisms.
The downward movement of the helix a-B and its effect on the
Gly-rich loop was the key factor that prompted the allosteric
conformational change that stabilized the active site of PDK1
in the presence of PS210. The downward movement of the
Gly-rich loop excluded water molecules from the ATP-binding
site and allowed us to visualize one divalent cation tethering
the b- and g-phosphates of ATP to Asp223 of the DFG motif,
which is similar to the close-active conformation of PKA. PDK1
has so far been crystallized in at least five crystal packings (Bio-
ndi et al., 2002; Hindie et al., 2009). Interestingly, in all previous
cases, the overall relative position of the small and large lobe
was ‘‘intermediate,’’ suggesting that this intermediate may be
the most stable conformation of the catalytic domain of PDK1
in solution as well as in crystal form. The interaction of PDK1
with the phosphorylated HM of substrates could, similarly to
PS210, fix residues at the phosphate-binding site and facilitate
the downward movement of the Gly-rich loop.
Previous experiments with PDK1 proteins that were mutated
at the PIF-binding pocket (e.g., Leu155Glu) showed that the
pocket was required for the docking, phosphorylation and acti-
vation of S6K but not PKB/Akt in vitro (Biondi et al., 2001) and
in vivo (Bayascas et al., 2006; Collins et al., 2003, 2005). Under
constitutive activation, S6K mediates an insulin signaling nega-
tive feedback loop in muscle, the previous work supported the
possibility of sensitizing muscle. We now show that small
compounds that bind to the PIF-binding pocket, even if they
are potent activators in vitro, selectively inhibit the phosphoryla-
tion and activation of S6K. This is in agreement with the previous
finding that the PDK1 Leu155Glumutant, that has higher specific
activity than the wild-type protein (Biondi et al., 2000), does not
increase the ability of PDK1 to activate PKB/Akt in vitro (Biondi
et al., 2001) or in vivo (Collins et al., 2003). It is possible that
the kinetics of the PKB/Akt- PIP3- PDK1 interaction and colocal-
ization are responsible for the absence of an activating effect of
PDK1 Leu155Glu and PS210 on PIP3-dependent phosphoryla-
tion of PKB/Akt. The di-ester derivative PS423 was an elegant
tool for probing a cellular system pharmacologically because
this molecule readily permeated cells and, once inside, was
cleaved to produce the active drug PS210. The treatment of
HEK293 and myoblast cells with PS423 inhibited S6K signaling
without affecting PKB/Akt phosphorylation and downstream
effects. The selectivity of the PS210 compound and the observa-
tion of its docking to the PIF-binding pocket of PDK1 indicated
that the intracellular blockage of the PIF-binding pocket trig-
gered the inhibition of S6K signaling. Thus, to our knowledge,
this is the first pharmacological evidence that blocking the PIF-
binding pocket with a small compound can lead to the selective
inhibition of S6K without affecting PKB/Akt. The selective inhibi-
tion of S6K is expected to inhibit the negative feedback loop
present in insulin-resistant cells and sensitize them to PKB/
Akt-dependent insulin actions. A context-dependent ATP-
competitive PDK1 inhibitor that inhibits weakly PKB/Akt was
previously described (Najafov et al., 2011). It is possible that
such compound binds to the most closed-active form of
PDK1, which may be stabilized by the docking interaction with
the PIF-pocket by most substrates but not be stabilized by
PKB. Interestingly, PS423 also allowed us to identify different1160 Chemistry & Biology 19, 1152–1163, September 21, 2012 ª201PDK1 downstream effectors that transduce glucose uptake in
response to insulin in C2C12myoblasts and in C2C12myotubes.
Thus, PS423 and future compounds blocking the PIF-binding
pocket of PDK1 may block insulin-stimulated glucose uptake
in nondifferentiated muscle cells. In one knock-in approach
where PDK1 Leu155Glu was heterozygously expressed in
mice (PDK1fl/155EMckCre+/), an increase in PKB/Akt phosphor-
ylation in response to insulin stimulation was observed (Bayas-
cas et al., 2006), suggesting that blocking the PIF-pocket could
sensitize organisms to insulin action and lead to drugs for the
treatment of insulin resistance and type 2 diabetes. However,
a second PDK1 Leu155Glu knock-in approach did not reveal
the same phenotype (Bayascas et al., 2006). The knock-in tech-
nique has the drawback of often generating compensatory
mechanisms that mask the actual effect of the mutation while
conditional knock-in can be incomplete or restricted to a subset
of cells in the organism and do not mimic the systemic action of
small molecule drugs. Therefore, the validation of the PIF-
binding pocket as a drug target will best be assessed by acute
pharmacologic treatment with compounds binding to the pocket
of PDK1. The PDK1 substrates S6K, RSK and SGK that require
docking to the PIF-binding pocket of PDK1, are also involved
in cancer progression (Pearce et al., 2010). Therefore, future
compounds blocking the pocket could also have potential use
for the treatment of diverse cancers.
Targeting allosteric sites in protein kinases with small mole-
cules is an emerging research area because it could overcome
drug resistance and lack-of-selectivity issues that are often
associated with the more classical ATP-competitive drugs.
Moreover, the targeting of truly allosteric sites, i.e., regulatory
sites, on protein kinases introduces the possibility both to
activate and to inhibit a particular kinase. In support of this
possibility, we recently showed that a compound binding to
the PIF-pocket could transduce the conformational changes
that lead to the allosteric inhibition of an AGC kinase, the atypical
PKCz (Fro¨hner et al., 2011; Lopez-Garcia et al., 2011). Thus,
the PIF-pocket of AGC kinases may be considered a site for
the development of agonists and antagonists of a conforma-
tional change, acting like a pharmacologic switch that can turn
enzymes ON or OFF. Notably, the data presented in the present
work confirm a third potential use of allosteric compounds:
the development of substrate-selective inhibitors. Since protein
kinases can function in different signaling pathways and can
also generate negative feedback loops, substrate-selective
inhibitors to protein kinases have immense potential for drug
discovery. In one example, targeting the differences in the
mechanism of substrate recognition of GSK3 was postulated
as an approach to obtain the desired effects on neurological
disorders or diabetes without affecting the Wnt-signaling
substrates and therefore avoiding the risk that the total inhibition
of GSK3 would support the development of colon cancers
(Frame et al., 2001).
The general model for the mechanism of activation of AGC
kinases byHMphosphorylation involves the intramolecular inter-
action of the HM with the PIF-pocket of its own kinase domain.
By binding to the PIF-binding pocket of PDK1, the compounds
mimicking the conformational change also block the interaction
of PDK1 with its substrate S6K. To our knowledge, the work
on the PIF-binding pocket of PDK1 provides the first example2 Elsevier Ltd All rights reserved
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ylation-dependent conformational changes in protein kinases
with small compounds and has led to the first rationally designed
substrate-selective inhibitor. Importantly, this shows that the
cellular substrate specificity of protein kinases cannot only be
explained by the standard ‘‘recognition motifs’’ located in short
segments of the primary sequence around the phosphorylation
site of substrates (Biondi and Nebreda, 2003). Therefore, the
existence of alternative mechanisms for substrate recognition,
such as docking interactions, allows the possibility of developing
substrate-selective inhibitors targeting a broader range of pro-
tein kinases.SIGNIFICANCE
Although protein phosphorylation is widely present in
human cells to transduce cellular signaling in both normal
physiology and disease, the phosphorylation-dependent
conformational changes induced in proteins are vastly un-
known. Also, the molecular mechanisms by which protein
kinases interact with substrates have not been broadly in-
vestigated. Consequently, phosphorylation-dependent con-
formational changes or substrate-selective inhibitors of
protein kinases are not considered as possible avenues for
the pharmacologic treatment of diseases. The understand-
ing of the mechanisms by which small compounds mimic
phosphorylation-dependent conformational changes in tar-
get proteins, or the mechanism of protein kinase interac-
tion with substrates, can potentially expand the druggable
genome to include new signaling molecules that regulate
substrate phosphorylation and phosphorylation-dependent
conformational changes. A characteristic of drugs that tar-
get regulatory sites is that they can trigger a different set of
conformational changes in target proteins, acting as activa-
tors or inhibitors of enzymatic activities, or, as here de-
scribed, as substrate-selective inhibitors. Indeed, we show
that the binding of a small molecule to the PIF-pocket regu-
latory site of PDK1, besides activating the kinase in vitro,
affects the mechanism by which PDK1 interacts with its
protein substrates and, in cells, acts as a substrate-selective
inhibitor of PDK1. The rational design of the substrate-selec-
tive inhibitorwasbasedon thedeepknowledgeof themolec-
ular mechanisms operating on PDK1. Hence, it is possible to
envisage that the better understanding of the mechanisms
that determine the interaction with substrates could lead to
the development of substrate-selective inhibitors of other
protein kinases. The present work also completes the
picture of the discovery of a phosphorylation-dependent
regulatory sitewith themolecular details showing theactiva-
tionprocessmimickedwith smallmolecules. Thework could
inspire the development of compounds to modulate the
activity of other AGC kinases and, more generally, of
enzymes regulated by phosphorylation.EXPERIMENTAL PROCEDURES
The materials and reagents used, the synthesis of small compounds, the
expression and purification of proteins, and the crystallization and structure
determination are described in the Supplemental Experimental Procedures.Chemistry & Biology 19, 1152–116Protein Kinase Activity Assay
The protein kinase activity assays were performed essentially as previously
described (Engel et al., 2006). The assays were performed in a 96-well format,
and 4 ml aliquots were spotted on P81 phosphocellulose papers (Whatman)
using an epMotion 5070 (Eppendorf). The papers were washed in 0.01%phos-
phoric acid, dried, and then exposed and analyzed using PhosphoImager
technology (FLA-9000 Starion, Fujifilm). PDK1 activity assays were performed
in a total volume of 20 ml containing 50 mM Tris-HCl (pH 7.4), 0.05 mg/ml BSA,
0.1% (v/v) b-mercaptoethanol, 10 mM MgCl2, 100 mM [g
32P]ATP (5–50 cpm/
pmol), 0.003% Brij, 300-600 ng PDK1 and 200 mM T308tide (KTFCGTPEYLA
PEVRR) as the substrate. After a 15 min preincubation, the kinase reaction
was initiated by the addition of the ATP-Mg mixture. To compare the
T308tide and PDKtide substrates, Brij was omitted from the reaction buffer
and 100 mM concentration of PDKtide (KTFCGTPEYLAPEVRREPRILSEEE
QEMFRDFDYIADWC) and 7 ng PDK1 were used.
The activity assays were performed in duplicate with less than a 10% differ-
ence observed between the duplicate pairs. The activity assays whose results
are shownwere repeated at least twice with similar results. There was variation
in themaximal activation of the compounds between different assays. The out-
sourced kinase profiling study was performed by the International Centre for
Kinase Profiling (MRC Protein Phosphorylation Unit, University of Dundee,
Scotland).
Differential Scanning Fluorimetry
Protein unfolding was monitored by the increase in the fluorescence of
the fluorophor SYPRO Orange (Invitrogen) using a real-time PCR device
(StepOnePlus, Applied Biosystems) following the protocol described by Nie-
sen et al. (Niesen et al., 2007). PDK1 was diluted in 10 mM HEPES (pH 7.5)
buffer containing 150 mM NaCl. The reactions were performed in a final
volume of 10 ml in 96-well PCR microtiter plates (Greiner) and contained
1 mM PDK1, 10 mM HEPES (pH 7.5), 150 mM NaCl, 1/1000 SYPRO Orange,
and 1mMdithiothreitol. PIFtide or compounds (1% final DMSO concentration)
were added to this reaction mixture. The temperature gradient was performed
in steps of 0.3C in the range of 25C to 70C. To calculate the Tm values, the
data were exported to GraphPad Prism and the curves fitted to a Boltzmann
sigmoidal equation with all R2 > 0.998.
Cell-Based Experiments
HEK293 cells were grown in 6-well culture dishes, serum starved overnight
and incubated for 2 hr with the compounds. All compound dilutions were
added as duplicates or triplicates. Cells treated with 0.2% DMSO served as
the controls. The cells were stimulated 20 min prior to lysis with 10 ng/ml
IGF1. The lysis was performed on ice in a buffer containing 50 mM Tris-HCl
(pH 7.4), 1 mMEGTA, 1mMEDTA, 1% (w/v) Triton X-100, 1mM sodium ortho-
vanadate, 50 mM sodium fluoride, 5 mM sodium pyrophosphate, 0.27 M
sucrose, 0.1% b-mercaptoethanol, and one tablet of protease inhibitor cock-
tail (Roche) per 50 ml of buffer.
C2C12 cells were preincubated for 2 or 4 hr with PS423 or DMSO. The acti-
vation of the PDK1 signaling pathway was achieved by incubating the cells for
15 or 60 min with 100 nM insulin.
For the western blot analysis, we used antibodies against phospho-S6
(Ser235/236 Cell Signaling), phospho-S6K [T229] (Novus Biologicals), phos-
pho-PKB [T308] (Cell Signaling), phospho-PKB [S437] (Cell Signaling), and
phospho-GSK3 (Cell Signaling). The IgG IRDye800CW secondary antibodies
(anti-mouse and anti-rabbit) were obtained from Li-Cor, and the Cy5-conju-
gated IgG antibodies (anti-mouse and anti-rabbit) were obtained from Invitro-
gen. The fluorescencewas detected on a Fuji FLA9000, and quantification was
performed using a Multi Gauge software (Fuji Film).
2-Deoxyglucose Uptake Assay
On the first day, 83 104 C2C12 cells were seeded on 24-wells plates (Falcon)
in growth medium and, on the second day, switched to DMEM with 2% horse
serum and 1% penicillin/streptomycin to induce differentiation. The differenti-
ation mediumwas replaced every 24 hr, and cells were used after 6 days. After
serum starvation for 3 hr, C2C12 myoblast and myotubes were washed once
with PBS and then incubated with DMSO, 25 mM PS423, 25 nM rapamycin,
and 25 mM UCN-01 for 1 hr at 37C. Subsequently, cells were stimulated
with 100 nM insulin for 30 min at 37C in medium without serum, and glucose3, September 21, 2012 ª2012 Elsevier Ltd All rights reserved 1161
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0.1 mM 2-deoxy-glucose/1 mCi 2-deoxy-[3H] glucose in Krebs-Ringer phos-
phate-HEPES buffer (KRPH buffer: 25 mM HEPES [pH 7.4], 1.3 mM MgSO4,
1.3 mM CaCl2, 118 mM NaCl, 4.8 mM KCl, 5 mM NaHCO3, 1.2 mM KH2PO4,
0.007% BSA). After a 4 min incubation, the reactions were stopped by the
addition of ice-cold PBS.
The cells were lysed using scintillation liquid (Insta-Gel Plus from Packard),
and the glucose uptake was assessed by scintillation counting using a 1450
Microbeta TRILUX reader (Wallac). Cytochalasin B (20 mM) was used to mea-
sure the nonspecific background because this drug blocks glucose uptake.
The results of the specific uptake were calculated by subtracting the back-
ground from the total uptake.ACCESSION NUMBERS
The RCSB Protein Data Bank (PDB) accession numbers for the crystal struc-
tures of the human PDK1 kinase domain in complex with compounds PS182
and PS210 reported in this paper are 4AW0 and 4AW1, respectively.SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, two tables, and Supplemental
Experimental Procedures and can be found with this article online at http://dx.
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